Project 2
NSCLC with brain metastases and EGFR mutations
Phase IIaActive
Key Facts
Indication
NSCLC with brain metastases and EGFR mutations
Phase
Phase IIa
Status
Active
Company
About Suzhou Teligene
Clinical-stage Chinese biotech developing brain-penetrant small molecule targeted therapies for oncology, with multiple programs in Phase I-II trials.
View full company profile